{"url":"https://nivawealth.com/firms/perceptive-advisors-154703","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/154703","regulatoryAum":11765315630,"crd":"154703","secFileNumber":"801-71841","legalName":"Perceptive Advisors LLC.","displayName":"Perceptive Advisors","website":null,"linkedinUrl":"https://www.linkedin.com/company/perceptive-advisors-llc/","founded":null,"organization":"Delaware limited liability company","fiscalYearEnd":"December","headquarters":{"street":"51 Astor Place, 10th FLR","city":"New York","state":"NY","stateName":"New York","country":"United States","postalCode":"10003"},"tradeNames":[],"registration":{"secApproved":"4 October 2010","noticeFilings":null,"latestNoticeFiling":null},"staff":{"employees":49,"advisory":28,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"discretionary":11765315630,"discretionaryAccounts":26,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":28,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":25,"regulatoryAum":11655707855},{"label":"Other","clients":1,"regulatoryAum":109607775}],"fees":[],"feeNotes":[],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[{"name":"Bofa Securities, Inc.","shortName":"Bofa Securities","location":"New York, NY","smaAssets":15435443}],"custodyNote":"Perceptive Advisors has custody of $11.77B for 26 clients.","otherCustodians":[],"leadership":[{"name":"Joseph Edelman","title":"Chief Executive Officer and Portfolio Manager","crd":"2115413"},{"name":"Shmuel Cohn","title":"Chief Financial Officer","crd":"8210928"},{"name":"James Mannix","title":"Chief Operating Officer","crd":"2347977"},{"name":"Alexander Rakitin","title":"Chief Compliance Officer","crd":"5841788"},{"name":"Marcel Rosner","title":"General Counsel","crd":"8058053"},{"name":"Adam Stone","title":"Chief Investment Officer","crd":"5139205"}],"ownership":[{"label":"Joseph Edelman","detail":"Chief executive officer and portfolio manager in the 75% or more ownership band and a control person, since December 2000."},{"label":"Adam Stone","detail":"Chief investment officer in the 10% to 25% ownership band and a control person, since December 2025."}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":4,"privateResidences":0},"listedOfficeAddresses":5,"officesByState":[{"state":"Connecticut","offices":1,"addresses":[{"street":"2 Greenwich Office Park","city":"Greenwich"}]},{"state":"Florida","offices":1,"addresses":[{"street":"929 Alton RD.","city":"Miami Beach"}]},{"state":"New York","offices":2,"addresses":[{"street":"51 Astor Place, 10th FLR","city":"New York","headquarters":true},{"street":"56 Flying Point Road","city":"Water Mill"}]},{"state":"Wyoming","offices":1,"addresses":[{"street":"145 North Connor Street","city":"Sheridan"}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"646-205-5300","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)","Other"],"financialPlanningClients":null,"assetMix":[{"label":"Exchange-traded equity securities","percent":18},{"label":"Non-exchange-traded equity securities","percent":64},{"label":"Non-investment grade corporate bonds","percent":2},{"label":"Securities issued by pooled investment vehicles (other than registered investment companies)","percent":16}],"privateFunds":17},"sources":{"adv1FilingDate":"13 July 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/154703/PDF/154703.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Perceptive Advisors have?","answer":"Perceptive Advisors has 26 clients and manages $11.8 billion for them, as of July 2026. They include 25 pooled investment vehicles and 1 other clients.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 13 July 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Perceptive Advisors offer?","answer":"Perceptive Advisors provides portfolio management for pooled vehicles and other activities.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Which custodians does Perceptive Advisors use?","answer":"Perceptive Advisors’ separately managed account assets are held at Bofa Securities, Inc. (New York, NY), with $15,435,443. Only custodians holding at least a tenth of those assets are named.","source":"Form ADV Part 1A, Schedule D, Section 5.K.(3), filed 13 July 2026","sourceRef":{"doc":"adv1","section":"custodians"}},{"question":"How many financial advisors does Perceptive Advisors have?","answer":"Perceptive Advisors has 0 investment adviser representatives registered with state securities authorities, out of 49 employees, and 28 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What does Perceptive Advisors invest in?","answer":"At the end of its last fiscal year, Perceptive Advisors’ separately managed accounts held 64% non-exchange-traded equities, 18% exchange-traded equities, 16% pooled vehicles (private funds and similar) and 2% high-yield corporate bonds. It advises 17 private funds.","source":"Form ADV Part 1A, Items 5.K.(1) and 7.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Perceptive Advisors?","answer":"Perceptive Advisors’ direct owners are Joseph Edelman (75% or more) and Adam Stone (10% to 25%).","source":"Form ADV Part 1A, Schedules A and B, filed 13 July 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Perceptive Advisors get paid?","answer":"Perceptive Advisors is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}}],"holdings":{"url":"https://nivawealth.com/firms/perceptive-advisors-154703/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-14","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1224962/000101297526000777/0001012975-26-000777-index.html","totalValue":6661817069,"positionCount":109,"top10Share":0.4730212113844521,"top10":[{"issuer":"PRAXIS PRECISION MEDICINES I","titleOfClass":"COM NEW","cusip":"74006W207","value":681627753,"shares":2035986,"shareType":"SH","priorValue":655974329,"priorShares":2035986},{"issuer":"SPYRE THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"00773J202","value":383484855,"shares":4319496,"shareType":"SH","priorValue":190825869,"priorShares":3783225},{"issuer":"CELCUITY INC","titleOfClass":"COM","cusip":"15102K100","value":334491064,"shares":3197200,"shareType":"SH","priorValue":356938608,"priorShares":3127200},{"issuer":"ASCENDIS PHARMA A/S","titleOfClass":"ORD SHS","cusip":"K08588103","value":310387665,"shares":1163721,"shareType":"SH"},{"issuer":"RHYTHM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"76243J105","value":287156334,"shares":2586295,"shareType":"SH","priorValue":206448951,"priorShares":2373795},{"issuer":"ROIVANT SCIENCES LTD","titleOfClass":"SHS","cusip":"G76279101","value":286144465,"shares":8085461,"shareType":"SH","priorValue":229507270,"priorShares":8285461},{"issuer":"RELAY THERAPEUTICS INC","titleOfClass":"COM","cusip":"75943R102","value":263926759,"shares":14106187,"shareType":"SH","priorValue":97023853,"priorShares":9751141},{"issuer":"TRAVERE THERAPEUTICS INC","titleOfClass":"COM","cusip":"89422G107","value":213183729,"shares":3752574,"shareType":"SH","priorValue":123075190,"priorShares":4142551},{"issuer":"KARDIGAN INC","titleOfClass":"COM","cusip":"485925101","value":195585788,"shares":8200662,"shareType":"SH"},{"issuer":"NUVALENT INC","titleOfClass":"COM","cusip":"670703107","value":195192368,"shares":1580505,"shareType":"SH","priorValue":161922737,"priorShares":1580505}],"positionsListed":109,"positions":[{"issuer":"PRAXIS PRECISION MEDICINES I","titleOfClass":"COM NEW","cusip":"74006W207","value":681627753,"shares":2035986,"shareType":"SH","priorValue":655974329,"priorShares":2035986},{"issuer":"SPYRE THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"00773J202","value":383484855,"shares":4319496,"shareType":"SH","priorValue":190825869,"priorShares":3783225},{"issuer":"CELCUITY INC","titleOfClass":"COM","cusip":"15102K100","value":334491064,"shares":3197200,"shareType":"SH","priorValue":356938608,"priorShares":3127200},{"issuer":"ASCENDIS PHARMA A/S","titleOfClass":"ORD SHS","cusip":"K08588103","value":310387665,"shares":1163721,"shareType":"SH"},{"issuer":"RHYTHM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"76243J105","value":287156334,"shares":2586295,"shareType":"SH","priorValue":206448951,"priorShares":2373795},{"issuer":"ROIVANT SCIENCES LTD","titleOfClass":"SHS","cusip":"G76279101","value":286144465,"shares":8085461,"shareType":"SH","priorValue":229507270,"priorShares":8285461},{"issuer":"RELAY THERAPEUTICS INC","titleOfClass":"COM","cusip":"75943R102","value":263926759,"shares":14106187,"shareType":"SH","priorValue":97023853,"priorShares":9751141},{"issuer":"TRAVERE THERAPEUTICS INC","titleOfClass":"COM","cusip":"89422G107","value":213183729,"shares":3752574,"shareType":"SH","priorValue":123075190,"priorShares":4142551},{"issuer":"KARDIGAN INC","titleOfClass":"COM","cusip":"485925101","value":195585788,"shares":8200662,"shareType":"SH"},{"issuer":"NUVALENT INC","titleOfClass":"COM","cusip":"670703107","value":195192368,"shares":1580505,"shareType":"SH","priorValue":161922737,"priorShares":1580505},{"issuer":"EDGEWISE THERAPEUTICS INC","titleOfClass":"COM","cusip":"28036F105","value":177714564,"shares":4373974,"shareType":"SH","priorValue":139355181,"priorShares":4423974},{"issuer":"APOGEE THERAPEUTICS INC","titleOfClass":"COM","cusip":"03770N101","value":173625838,"shares":1308113,"shareType":"SH","priorValue":129654121,"priorShares":1540384},{"issuer":"AMYLYX PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"03237H101","value":149694481,"shares":8334882,"shareType":"SH","priorValue":115159860,"priorShares":8284882},{"issuer":"MEIRAGTX HLDGS PLC","titleOfClass":"COM","cusip":"G59665102","value":145727749,"shares":10786658,"shareType":"SH","priorValue":89312864,"priorShares":10326103},{"issuer":"ORUKA THERAPEUTICS INC","titleOfClass":"COM","cusip":"687604108","value":128009646,"shares":1345063,"shareType":"SH","priorValue":68449324,"priorShares":1395501},{"issuer":"INHIBRX BIOSCIENCES INC","titleOfClass":"COM","cusip":"45720N103","value":122963044,"shares":1297763,"shareType":"SH","priorValue":96993192,"priorShares":1442707},{"issuer":"PROTAGONIST THERAPEUTICS INC","titleOfClass":"COM","cusip":"74366E102","value":120358728,"shares":981879,"shareType":"SH","priorValue":129734647,"priorShares":1230879},{"issuer":"SOLID BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"83422E204","value":118947393,"shares":11906646,"shareType":"SH","priorValue":85727851,"priorShares":11906646},{"issuer":"ZYMEWORKS INC","titleOfClass":"COM","cusip":"98985Y108","value":109342391,"shares":4182953,"shareType":"SH","priorValue":87892353,"priorShares":3510078},{"issuer":"TANGO THERAPEUTICS INC","titleOfClass":"COM","cusip":"87583X109","value":105565020,"shares":3377000,"shareType":"SH","priorValue":16906561,"priorShares":808153},{"issuer":"IMMATICS N.V","titleOfClass":"SHS","cusip":"N44445109","value":105184409,"shares":10383456,"shareType":"SH","priorValue":102173207,"priorShares":10383456},{"issuer":"NURIX THERAPEUTICS INC","titleOfClass":"COM","cusip":"67080M103","value":104813438,"shares":4320422,"shareType":"SH","priorValue":57518594,"priorShares":3710877},{"issuer":"BIOCRYST PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"09058V103","value":103088880,"shares":10308888,"shareType":"SH","priorValue":70771994,"priorShares":7434033},{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"COM","cusip":"76155X100","value":98808928,"shares":527600,"shareType":"SH","priorValue":25148850,"priorShares":258600},{"issuer":"AVALYN PHARMACEUTICALS INC","titleOfClass":"COM SHS","cusip":"05348Y105","value":88070744,"shares":2675296,"shareType":"SH"},{"issuer":"MODERNA INC","titleOfClass":"COM","cusip":"60770K107","value":70030000,"shares":1000000,"shareType":"SH","putCall":"Put","priorValue":50800000,"priorShares":1000000},{"issuer":"DYNE THERAPEUTICS INC","titleOfClass":"COM","cusip":"26818M108","value":59727909,"shares":2689235,"shareType":"SH","priorValue":84646051,"priorShares":4668839},{"issuer":"BIOGEN INC","titleOfClass":"COM","cusip":"09062X103","value":59669938,"shares":276173,"shareType":"SH"},{"issuer":"IMMUNOVANT INC","titleOfClass":"COM","cusip":"45258J102","value":52299967,"shares":1357383,"shareType":"SH","priorValue":39678994,"priorShares":1597383},{"issuer":"UNITEDHEALTH GROUP INC","titleOfClass":"COM","cusip":"91324P102","value":48548078,"shares":116806,"shareType":"SH"},{"issuer":"SPDR SERIES TRUST","titleOfClass":"ST STR SP BIOT","cusip":"78464A870","value":47475000,"shares":300000,"shareType":"SH","putCall":"Put"},{"issuer":"IONIS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"462222100","value":44878140,"shares":566000,"shareType":"SH","priorValue":37845360,"priorShares":504000},{"issuer":"SUTRO BIOPHARMA INC","titleOfClass":"COM SHS","cusip":"869367201","value":43320887,"shares":1304846,"shareType":"SH","priorValue":17818297,"priorShares":715307},{"issuer":"ALTO NEUROSCIENCE INC","titleOfClass":"COM SHS","cusip":"02157Q109","value":42485076,"shares":1609893,"shareType":"SH","priorValue":45182395,"priorShares":2009893},{"issuer":"JAZZ PHARMACEUTICALS PLC","titleOfClass":"SHS USD","cusip":"G50871105","value":40964900,"shares":170000,"shareType":"SH","priorValue":32138500,"priorShares":170000},{"issuer":"CORVUS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"221015100","value":39851569,"shares":2667441,"shareType":"SH","priorValue":33538412,"priorShares":2292441},{"issuer":"SIONNA THERAPEUTICS INC","titleOfClass":"COM","cusip":"829401108","value":39810950,"shares":905000,"shareType":"SH","priorValue":26396820,"priorShares":658439},{"issuer":"CYTOMX THERAPEUTICS INC.","titleOfClass":"COM","cusip":"23284F105","value":39146944,"shares":10439185,"shareType":"SH","priorValue":47464473,"priorShares":10098824},{"issuer":"ARTIVION INC","titleOfClass":"COM","cusip":"228903100","value":39036906,"shares":1737290,"shareType":"SH","priorValue":59957560,"priorShares":1637290},{"issuer":"X4 PHARMACEUTICALS INC","titleOfClass":"COM NEW","cusip":"98420X202","value":37049403,"shares":7933491,"shareType":"SH","priorValue":27826486,"priorShares":6737648},{"issuer":"CORCEPT THERAPEUTICS INC","titleOfClass":"COM","cusip":"218352102","value":34639576,"shares":398385,"shareType":"SH","priorValue":2015500,"priorShares":50000},{"issuer":"REPLIGEN CORP","titleOfClass":"COM","cusip":"759916109","value":33866045,"shares":248212,"shareType":"SH","priorValue":33053341,"priorShares":280541},{"issuer":"ANTERIS TECHNOLOGIES GLOBAL","titleOfClass":"COM","cusip":"03675P102","value":33740939,"shares":3425476,"shareType":"SH","priorValue":19011392,"priorShares":3425476},{"issuer":"RAPPORT THERAPEUTICS INC","titleOfClass":"COM","cusip":"75383L102","value":32225161,"shares":773342,"shareType":"SH","priorValue":21087051,"priorShares":673923},{"issuer":"DAMORA THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"36322Q206","value":31810230,"shares":1223000,"shareType":"SH","priorValue":31675700,"priorShares":1223000},{"issuer":"CHARLES RIV LABS INTL INC","titleOfClass":"COM","cusip":"159864107","value":31750600,"shares":140000,"shareType":"SH"},{"issuer":"AXSOME THERAPEUTICS INC.","titleOfClass":"COM","cusip":"05464T104","value":28993007,"shares":118450,"shareType":"SH","priorValue":25344549,"priorShares":149950},{"issuer":"EYEPOINT INC","titleOfClass":"COM NEW","cusip":"30233G209","value":28600000,"shares":2000000,"shareType":"SH","putCall":"Put"},{"issuer":"DBV TECHNOLOGIES S A","titleOfClass":"SPONSORED ADS","cusip":"23306J309","value":27114940,"shares":1653350,"shareType":"SH","priorValue":20146128,"priorShares":964391},{"issuer":"IRHYTHM HOLDINGS INC","titleOfClass":"COM","cusip":"450056106","value":26616966,"shares":223766,"shareType":"SH","priorValue":12395169,"priorShares":105026},{"issuer":"ADAPTIVE BIOTECHNOLOGIES COR","titleOfClass":"COM","cusip":"00650F109","value":26111621,"shares":1217325,"shareType":"SH","priorValue":2116700,"priorShares":152500},{"issuer":"SAB BIOTHERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"78397T202","value":25847254,"shares":6627501,"shareType":"SH","priorValue":24633576,"priorShares":6431743},{"issuer":"DANAHER CORP DEL","titleOfClass":"COM","cusip":"235851102","value":24762400,"shares":130000,"shareType":"SH"},{"issuer":"TENAX THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"88032L605","value":24735000,"shares":1700000,"shareType":"SH","priorValue":23150034,"priorShares":1447782},{"issuer":"CAPRICOR THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"14070B309","value":24080000,"shares":1000000,"shareType":"SH","putCall":"Call"},{"issuer":"SELLAS LIFE SCIENCES GROUP I","titleOfClass":"COM NEW","cusip":"81642T209","value":22140000,"shares":1500000,"shareType":"SH","putCall":"Put"},{"issuer":"NAUTILUS BIOTECHNOLOGY INC","titleOfClass":"COM","cusip":"63909J108","value":21755974,"shares":11634211,"shareType":"SH","priorValue":48865538,"priorShares":12594211},{"issuer":"ORCHESTRA BIOMED HLDGS INC","titleOfClass":"COM","cusip":"68572M106","value":21738564,"shares":5037906,"shareType":"SH","priorValue":21411101,"priorShares":5037906},{"issuer":"INTUITIVE SURGICAL INC","titleOfClass":"COM NEW","cusip":"46120E602","value":20633229,"shares":51884,"shareType":"SH","priorValue":39377305,"priorShares":85419},{"issuer":"ADLAI NORTYE LTD","titleOfClass":"SPONSORED ADS","cusip":"00704R109","value":20621685,"shares":1793190,"shareType":"SH"},{"issuer":"CONTINEUM THERAPEUTICS INC","titleOfClass":"CL A","cusip":"21217B100","value":20579153,"shares":1255592,"shareType":"SH","priorValue":16398032,"priorShares":1255592},{"issuer":"NUVECTIS PHARMA INC","titleOfClass":"COM","cusip":"67080T108","value":18390000,"shares":1000000,"shareType":"SH"},{"issuer":"PALISADE BIO INC","titleOfClass":"COM","cusip":"696389402","value":17608386,"shares":8425065,"shareType":"SH","priorValue":15624261,"priorShares":8928149},{"issuer":"OMADA HEALTH INC","titleOfClass":"COM","cusip":"68170A108","value":17259943,"shares":786330,"shareType":"SH","priorValue":9884168,"priorShares":786330},{"issuer":"LEONABIO INC","titleOfClass":"COM","cusip":"04746L203","value":17087169,"shares":1859322,"shareType":"SH","priorValue":19113830,"priorShares":1859322},{"issuer":"EVOLUS INC","titleOfClass":"COM","cusip":"30052C107","value":17067438,"shares":2459285,"shareType":"SH","priorValue":5289003,"priorShares":1286862},{"issuer":"NEWAMSTERDAM PHARMA COMPANY","titleOfClass":"ORDINARY SHARES","cusip":"N62509109","value":16945000,"shares":500000,"shareType":"SH","putCall":"Put"},{"issuer":"INVIVYD INC","titleOfClass":"COM","cusip":"00534A102","value":16131231,"shares":18490636,"shareType":"SH","priorValue":27117094,"priorShares":20859303},{"issuer":"CELCUITY INC","titleOfClass":"NOTE  2.750% 8/0","cusip":"15102KAA8","value":14629442,"shares":6500000,"shareType":"PRN","priorValue":15875774,"priorShares":6500000},{"issuer":"MIRUM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"604749101","value":13508824,"shares":115391,"shareType":"SH"},{"issuer":"SURROZEN INC","titleOfClass":"COM NEW","cusip":"86889P208","value":13078411,"shares":503985,"shareType":"SH","priorValue":6682218,"priorShares":229393},{"issuer":"BETA BIONICS INC","titleOfClass":"COM","cusip":"08659B102","value":13052232,"shares":832944,"shareType":"SH","priorValue":8446299,"priorShares":842944},{"issuer":"CAPRICOR THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"14070B309","value":12040000,"shares":500000,"shareType":"SH","putCall":"Put"},{"issuer":"AXOGEN INC","titleOfClass":"COM","cusip":"05463X106","value":11423341,"shares":247312,"shareType":"SH","priorValue":23101947,"priorShares":697312},{"issuer":"OSCAR HEALTH INC","titleOfClass":"CL A","cusip":"687793109","value":11408000,"shares":400000,"shareType":"SH"},{"issuer":"OCULIS HOLDING AG","titleOfClass":"ORDINARY SHARES","cusip":"H5870P102","value":11218430,"shares":808827,"shareType":"SH","priorValue":13130860,"priorShares":493827},{"issuer":"SEAPORT THERAPEUTICS INC","titleOfClass":"COMMON STOCK","cusip":"81221K108","value":10860000,"shares":500000,"shareType":"SH"},{"issuer":"VIRIDIAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"92790C104","value":10690973,"shares":581980,"shareType":"SH","priorValue":22901415,"priorShares":1170829},{"issuer":"BOSTON SCIENTIFIC CORP","titleOfClass":"COM","cusip":"101137107","value":10670000,"shares":250000,"shareType":"SH"},{"issuer":"BILLIONTOONE INC","titleOfClass":"CL A","cusip":"090168105","value":10415704,"shares":86812,"shareType":"SH","priorValue":7247639,"priorShares":91812},{"issuer":"ABIVAX SA","titleOfClass":"SPONSORED ADS","cusip":"00370M103","value":9861240,"shares":74000,"shareType":"SH","priorValue":36621233,"priorShares":328884},{"issuer":"NATERA INC","titleOfClass":"COM","cusip":"632307104","value":9416329,"shares":34689,"shareType":"SH"},{"issuer":"ENGENE THERAPEUTICS INC","titleOfClass":"COM","cusip":"29286X101","value":8342352,"shares":4822169,"shareType":"SH"},{"issuer":"RESEARCH ALLIANCE CORP III","titleOfClass":"ORD SHS CL A","cusip":"G75226103","value":8025000,"shares":750000,"shareType":"SH"},{"issuer":"AGOMAB THERAPEUTICS NV","titleOfClass":"SPONSORED ADS","cusip":"00860C102","value":7788000,"shares":600000,"shareType":"SH","priorValue":6294000,"priorShares":600000},{"issuer":"CULLINAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"230031106","value":7766164,"shares":426478,"shareType":"SH"},{"issuer":"UNIQURE NV","titleOfClass":"SHS","cusip":"N90064101","value":7738080,"shares":168000,"shareType":"SH"},{"issuer":"MOBIA MED INC","titleOfClass":"COMMON STOCK","cusip":"60705V103","value":7016963,"shares":523654,"shareType":"SH"},{"issuer":"ADAGIO MED HLDGS INC","titleOfClass":"COM","cusip":"00534B100","value":6439534,"shares":9876586,"shareType":"SH","priorValue":11012382,"priorShares":9876576},{"issuer":"GUARDANT HEALTH INC","titleOfClass":"COM","cusip":"40131M109","value":6200290,"shares":41327,"shareType":"SH","priorValue":27711000,"priorShares":300000},{"issuer":"PHATHOM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"71722W107","value":5772200,"shares":532000,"shareType":"SH","priorValue":10276750,"priorShares":925000},{"issuer":"OUTLOOK THERAPEUTICS INC","titleOfClass":"COM","cusip":"69012T305","value":4991353,"shares":3139216,"shareType":"SH"},{"issuer":"COGENT BIOSCIENCES INC","titleOfClass":"COM","cusip":"19240Q201","value":4685873,"shares":121082,"shareType":"SH","priorValue":4660446,"priorShares":121082},{"issuer":"EDESA BIOTECH INC","titleOfClass":"COM NEW","cusip":"27966L306","value":4579133,"shares":563239,"shareType":"SH","priorValue":2945740,"priorShares":563239},{"issuer":"AVALO THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"05338F306","value":4062144,"shares":219813,"shareType":"SH","priorValue":2085228,"priorShares":139667},{"issuer":"TWIST BIOSCIENCE CORP","titleOfClass":"COM","cusip":"90184D100","value":3787219,"shares":36812,"shareType":"SH","priorValue":7128000,"priorShares":150000},{"issuer":"CRESCENT BIOPHARMA INC.","titleOfClass":"COM","cusip":"G2545C104","value":3724956,"shares":206942,"shareType":"SH","priorValue":3801525,"priorShares":206942},{"issuer":"XERIS BIOPHARMA HOLDINGS INC","titleOfClass":"COM","cusip":"98422E103","value":3698743,"shares":467013,"shareType":"SH"},{"issuer":"OUTSET MED INC","titleOfClass":"COM NEW","cusip":"690145206","value":3599998,"shares":833333,"shareType":"SH","priorValue":3199998,"priorShares":833333},{"issuer":"BIODESIX INC","titleOfClass":"COM","cusip":"09075X207","value":2451049,"shares":108694,"shareType":"SH"},{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"*W EXP 12/17/202","cusip":"76155X118","value":2344975,"shares":250000,"shareType":"SH","priorValue":447500,"priorShares":250000},{"issuer":"CONNECT BIOPHARMA HLDGS LTD","titleOfClass":"SHS","cusip":"G23549101","value":1886616,"shares":792696,"shareType":"SH","priorValue":2076864,"priorShares":792696},{"issuer":"KIORA PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"49721T507","value":1153179,"shares":438471,"shareType":"SH"},{"issuer":"MEDLINE INC","titleOfClass":"COM CL A","cusip":"58507V107","value":1104320,"shares":28000,"shareType":"SH","priorValue":1246000,"priorShares":28000},{"issuer":"ADMA BIOLOGICS INC","titleOfClass":"COM","cusip":"000899104","value":952213,"shares":113765,"shareType":"SH","priorValue":4209769,"priorShares":467233},{"issuer":"CUMBERLAND PHARMACEUTICALS I","titleOfClass":"COM","cusip":"230770109","value":628443,"shares":96982,"shareType":"SH","priorValue":640179,"priorShares":196978},{"issuer":"EXAGEN INC","titleOfClass":"COM","cusip":"30068X103","value":534252,"shares":114893,"shareType":"SH","priorValue":344679,"priorShares":114893},{"issuer":"ENSYSCE BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"293602504","value":25133,"shares":86666,"shareType":"SH","priorValue":46670,"priorShares":86666},{"issuer":"SURROZEN INC","titleOfClass":"*W EXP 08/01/203","cusip":"86889P117","value":2750,"shares":166666,"shareType":"SH","priorValue":2667,"priorShares":166666}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva Wealth is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}